<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02385188</url>
  </required_header>
  <id_info>
    <org_study_id>NL51648.091.14</org_study_id>
    <nct_id>NCT02385188</nct_id>
  </id_info>
  <brief_title>Topical 5% Imiquimod Cream for Vulvar Paget's Disease</brief_title>
  <official_title>Topical 5% Imiquimod Cream for Vulvar Paget's Disease: Clinical Efficacy, Safety and Immunological Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Nijmegen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Nijmegen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety and immunological response of
      topical 5% imiquimod cream for non-invasive vulvar Paget's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vulvar Paget's disease is a rare skin tumour and generally seen in postmenopausal, Caucasian
      women as an erythematous, eczematous, scaling or ulcerating plaque. Initial symptoms are
      irritation, burning, pain and a skin lesion. The origin of vulvar Paget's disease is not yet
      entirely understood. The treatment of choice is surgical excision, despite high recurrence
      rates. The mutilating consequences of surgery can lead to impressive morbidity to address
      this, several series report the use of topical 5% imiquimod cream for vulvar Paget's disease.

      The objective of this study is to assess the efficacy, evaluate the safety, immunological
      effect of topical 5% imiquimod cream for vulvar Paget's disease and the quality of life
      during treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response</measure>
    <time_frame>12 weeks after the end of treatment</time_frame>
    <description>Clinical response will be assessed by vulvar examination and measurement and is defined as complete remission, partial remission (decrease by â‰¥50% of total lesion size) or no remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability questionnaire</measure>
    <time_frame>4, 10 and 16 weeks after the start of treatment</time_frame>
    <description>Tolerability will be assessed in a descriptive manner with a tolerability questionnaire with the following questions:
Have you used paracetamol during treatment?
How many days?
What dosage?
Was the use sufficient?
Have you used lidocaine in Vaseline ointment during treatment?
How many days?
What dosage?
Was the use sufficient?
Have you stopped the treatment with imiquimod because of side effects/pain?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4, 10 and 16 weeks after the start of treatment</time_frame>
    <description>Most common adverse events will be evaluated with the following questions:
Have you been nauseous? No / a little (less than 3 days per week) / severe (more than 3 days a week) / Yes, daily.
Have you had a head ache? No / a little (less than 3 days per week) / severe (more than 3 days a week) / Yes, daily.
Have you felt more tired than you normally are? No / a little (less than 3 days per week) / severe (more than 3 days a week) / Yes, daily.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological response</measure>
    <time_frame>Baseline, 4 and 28 weeks after start of treatment</time_frame>
    <description>Vulvar skin biopsies will be taken at baseline, 4 and 28 weeks after the start of</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: general.</measure>
    <time_frame>Baseline, 4 and 28 weeks after start of treatment.</time_frame>
    <description>The questionnaire EQ5D (EuroQOL 5 Dimensions questionnaire) will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: dermatology specific.</measure>
    <time_frame>Baseline, 4 and 28 weeks after start of treatment.</time_frame>
    <description>The questionnaire DLQI (Dermatology Life Quality Index) will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: sexuality.</measure>
    <time_frame>Baseline, 4 and 28 weeks after start of treatment.</time_frame>
    <description>The questionnaire FSDS (Female Sexual Distress Scale) will be used.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Paget Disease, Extramammary</condition>
  <arm_group>
    <arm_group_label>Imiquimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical 5% imiquimod cream will be applicated to the vulvar skin lesion 3 times a week during 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>topical 5% imiquimod cream 3 times a week for 16 weeks.</description>
    <arm_group_label>Imiquimod</arm_group_label>
    <other_name>Aldara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol</intervention_name>
    <arm_group_label>Imiquimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine in Vaseline ointment</intervention_name>
    <arm_group_label>Imiquimod</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-invasive vulvar Paget's disease, primary or recurrence after earlier surgery;

          -  Willing and able to comply with the protocol and to provide informed consent in
             accordance with institutional and regulatory guidelines.

        Exclusion Criteria:

          -  Invasive vulvar Paget's disease;

          -  Underlying adenocarcinoma;

          -  Treatment of the vulva with topical 5% imiquimod cream during the last 6 months;

          -  Participation in a study with another investigational product within 30 days prior to
             enrolment in this study;

          -  Hypersensitivity to any component of topical 5% imiquimod cream (methylhydroxybenzoate
             (E218), propylhydroxybenzoate (E216), cetylalcohol, atearylalcohol);

          -  Patients with autoimmune disorders;

          -  Immune compromised patients (e.g. HIV patients, patients with a history of
             transplantation);

          -  Insufficient understanding of the Dutch or English language;

          -  Pregnant women;

          -  Lactating women.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne de Hullu, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>May 6, 2018</last_update_submitted>
  <last_update_submitted_qc>May 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Nijmegen</investigator_affiliation>
    <investigator_full_name>Joanne A. de Hullu, MD, PhD</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Extramammary Paget's disease</keyword>
  <keyword>Vulva</keyword>
  <keyword>Genital, female</keyword>
  <keyword>imiquimod</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paget Disease, Extramammary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Imiquimod</mesh_term>
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

